ライフサイエンスコーパス: olanzapine

1 c, haloperidol or an atypical antipsychotic, olanzapine.

2 d with the most widely used medication, oral olanzapine.

3 ence of baseline severity on the efficacy of olanzapine.

4 n of the atypical neuroleptics clozapine and olanzapine.

5 ble change in HDL cholesterol and girth with olanzapine.

6 a distinct mechanism different from that of olanzapine.

7 admission (30.8%) among neonates exposed to olanzapine.

8 spectrum disorders treated with clozapine or olanzapine.

9 eight gain, but weight gain was greater with olanzapine.

10 eated with quetiapine or risperidone but not olanzapine.

11 eeks of treatment with either risperidone or olanzapine.

12 ater improvement between weeks 8 and 28 with olanzapine.

13 th risperidone and 1.2 (95% CI=1.0-1.4) with olanzapine.

14 d toxicity or greater therapeutic effects of olanzapine.

15 iapine (HR, 1.34; 95% CI, 1.07-1.69) but not olanzapine.

16 07; P = .001) but not quetiapine fumarate or olanzapine.

17 ivity, as well as response to treatment with olanzapine.

18 6145 were one-fifth as likely to discontinue olanzapine.

19 0.33 mg/kg, IP) and the efficacious dose of olanzapine (0.033 mg/kg, IP) in combination with either

20 1.27-2.82, p=0.002), but not those receiving olanzapine (0.32, 0.21-0.49, p<0.0001).

21 sulpride (SMD -0.37, 95% CI -0.61 to -0.14), olanzapine (-0.25, -0.39 to -0.12), ziprasidone (-0.25,

22 e CATIE neurocognitive battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidon

23 of Cognition in Schizophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidon

24 X, 50 mg/kg, combined with the atypical APDs olanzapine (1.0 mg/kg) or aripiprazole (0.3 mg/kg) signi

25 done (1.7%; 95% CI, 0.6%-2.8%; P = .003) and olanzapine (1.5%; 95% CI, 0.02%-3.0%; P = .047).

26 d maintained stability on an oral regimen of olanzapine (10, 15, or 20 mg/day) for 4 to 8 weeks were

27 ular olanzapine or haloperidol injection=62, olanzapine=144, placebo=75, quetiapine=125, risperidone=

28 Overall, 24% of patients who received olanzapine, 16% of patients who received quetiapine, 18%

29 were administered the atypical antipsychotic olanzapine (2.5 mg/kg) twice daily for 28 days.

30 Subjects received either olanzapine (2.5-20 mg/day [N=107]) or placebo (N=54).

31 8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).

32 nts were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day),

33 rs) were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day),

34 oaffective disorder to treatment with either olanzapine (2.5-20 mg/day), risperidone (0.5-6 mg/day),

35 ding order were 2.79 (95% CI, 1.97-3.96) for olanzapine, 2.46 (95% CI, 1.94-3.12) for risperidone, an

36 P < .01) with an NNH of 27 (95% CI, 19-46); olanzapine, 2.5% (95% CI, 0.3%-4.7%; P = .02) with an NN

37 treatment due to a lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as

38 was observed in 32% of patients assigned to olanzapine, 26% of patients assigned to quetiapine, 29%

39 nt groups in response rates (molindone: 50%; olanzapine: 34%; risperidone: 46%) or magnitude of sympt

40 ontained data for 939 patients (552 received olanzapine; 387 received placebo).

41 y examining two drug samples, Olanzapine and Olanzapine-4' N-oxide.

42 roate (392; 95% CI, 334-460 per 10000 PYAR), olanzapine (409; 95% CI, 345-483 per 10000 PYAR), or que

43 e rates did not significantly differ between olanzapine (43.7%, 95% CI=28.8%-58.6%) and risperidone (

44 Outpatients received olanzapine (5-15 mg/day, N=31) or placebo (N=29) during

45 l (2-20 mg/d), or an atypical antipsychotic, olanzapine (5-20 mg/d).

46 an modal daily dose was 11.7 mg (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (

47 odal prescribed daily doses were 11.7 mg for olanzapine, 506 mg for quetiapine, and 2.4 mg for risper

48 ed with risperidone (median: 7.0 months) and olanzapine (6.3 months) than with quetiapine (4.0 months

49 2.9%) than with 40 mg of lurasidone (11.8%), olanzapine (7.4%), or placebo (0.9%).

50 nd treatment with a different antipsychotic (olanzapine, 7.5-30 mg/day [N=66]; quetiapine, 200-800 mg

51 t one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine

52 ignificantly longer among patients receiving olanzapine (a median of 174 days, compared with a median

53 Like clozapine, olanzapine acts via alpha7 nicotinic receptors to elicit

54 Although olanzapine alleviated cognitive deficits produced by neo

55 Similar to results from a past study, olanzapine alleviated cognitive impairment on the MWM pl

56 tory processing deficit, were obtained after olanzapine alone (0.01, 0.033, 0.1, 0.33 mg/kg, IP) and

57 We found that olanzapine, an AAP highly associated with weight gain, c

58 This effect was blocked by olanzapine, an antagonist of 5-HT1/2A receptors.

59 e weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidon

60 .8-25.7) versus 28.2 (95% CI=26.7-29.7) with olanzapine and 23.9 (95% CI=22.5-25.3) versus 26.7 (95%

61 receive treatment with either ziprasidone or olanzapine and followed for 1 year by unblinded investig

62 Clozapine was superior to both olanzapine and haloperidol in reducing the number and se

63 efully consider the benefit-to-risk ratio of olanzapine and its additional, prophylactic effect again

64 Clozapine shows greater efficacy than olanzapine and olanzapine greater efficacy than haloperi

65 od was tested by examining two drug samples, Olanzapine and Olanzapine-4' N-oxide.

66 ter the magnitude of the differences between olanzapine and placebo was expected.

67 s associated with weight gain in women, with olanzapine and quetiapine in particular, and with unfavo

68 Olanzapine and quetiapine treatments were significantly

69 With olanzapine and quetiapine, respectively, mean levels inc

70 and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).

71 reater in the perphenazine group than in the olanzapine and risperidone groups.

72 n the Clinical Global Impression of Changes, olanzapine and risperidone on the Brief Psychiatric Rati

73 Olanzapine and risperidone showed declining rates and qu

74 Olanzapine and risperidone were associated with signific

75 Individuals randomly assigned to olanzapine and risperidone who were continuing with thei

76 ety of two second-generation antipsychotics (olanzapine and risperidone) with a first-generation anti

77 c drugs (APDs), e.g. clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive functio

78 , 1670 prescribed valproate, 1477 prescribed olanzapine, and 1376 prescribed quetiapine as maintenanc

79 ents who could be evaluated (192 assigned to olanzapine, and 188 to placebo).

80 n 8 week, double-blind study of risperidone, olanzapine, and haloperidol.

81 idazolam, clozapine, terfenadine, erlotinib, olanzapine, and moxifloxacin) in multiple tissues after

82 rigine, topiramate, valproate, aripiprazole, olanzapine, and omega-3 fatty acid supplementation.

83 prescribed lithium, those taking valproate, olanzapine, and quetiapine had reduced rates of chronic

84 f greater than 15% weight gain on valproate, olanzapine, and quetiapine were higher (valproate HR 1.6

85 es during treatment with lithium, valproate, olanzapine, and quetiapine.

86 es with risperidone were equal to those with olanzapine, and response may be more stable.

87 .12 and 0.20 were observed for aripiprazole, olanzapine, and risperidone.

88 ant benefits were observed for aripiprazole, olanzapine, and risperidone.

89 sychotics other than clozapine, haloperidol, olanzapine, and risperidone.

90 reatment of affective disorders (quetiapine, olanzapine, and semisodium valproate) during the same pe

91 s, specifically quetiapine, risperidone, and olanzapine, are known to cause acute kidney injury (AKI)

92 gain or psychiatric disease, we administered olanzapine, aripiprazole, or placebo for 9 days to healt

93 also analyzed time to discontinuation in the olanzapine arm of the CATIE study.

94 was evaluated in schizophrenic patients with olanzapine as an active control in a randomized, three-a

95 hors investigated the efficacy and safety of olanzapine as monotherapy in relapse prevention in bipol

96 monstrating efficacy similar to that of oral olanzapine as well as to each other.

97 Olanzapine, as compared with placebo, significantly impr

98 isk also received aprepitant with or without olanzapine, based on their risk level.

99 to the therapeutic effects of clozapine and olanzapine, both highly effective therapeutics with sign

100 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated

101 haloperidol, aripiprazole, risperidone, and olanzapine, but, again, evidence was very low to low qua

102 INTERPRETATION: Benefits of olanzapine can be expected for patients across the full

103 A pattern of superiority for olanzapine, clozapine, and risperidone was seen in other

104 f life, except for worsened functioning with olanzapine compared to placebo.

105 Compared to placebo, olanzapine delays relapse into subsequent mood episodes

106 Risperidone and olanzapine did not demonstrate superior efficacy over mo

107 IMS analysis of tissues from 8 mg/kg olanzapine dosed rats revealed temporal distribution of

108 e rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P<0

109 ll patients seem to benefit less in terms of olanzapine efficacy, but still experience the same side-

110 weeks, with a safety profile similar to oral olanzapine except for injection-related adverse events.

111 Collectively, our studies suggest that olanzapine exerts some of its untoward metabolic effects

112 amate continued to produce positive results, olanzapine failed to show superior outcomes compared wit

113 ents included weight gain (particularly with olanzapine), fatigue, sedation, akathisia (for aripipraz

114 treatment also improved glucose tolerance in olanzapine-fed mice.

115 tified 14 short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and

116 treatment-resistant depression (TRD) taking olanzapine/fluoxetine combination (OFC).

117 responded to open-label acute treatment with olanzapine for a manic or mixed episode.

118 ically important benefit of haloperidol over olanzapine for improving positive symptoms, but the bene

119 We examined the efficacy of olanzapine for the prevention of nausea and vomiting in

120 y was to evaluate the efficacy and safety of olanzapine for the treatment of acute manic or mixed epi

121 the open-label phase, patients who received olanzapine gained a mean of 3.1 kg (SD=3.4).

122 (SD=4.4) and patients who continued to take olanzapine gained an additional 1.0 kg (SD=5.2).

123 e shows greater efficacy than olanzapine and olanzapine greater efficacy than haloperidol in reducing

124 esponding to treatment, more subjects in the olanzapine group (40.9%, 95% CI=16.8%-65.0%) than in the

125 relapse rate was significantly lower in the olanzapine group (46.7%) than in the placebo group (80.1

126 positive subscale scores were greater in the olanzapine group (at 12 weeks and at 52 weeks or withdra

127 romal positive symptoms improved more in the olanzapine group than in the placebo group, and the mixe

128 or any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or ris

129 he lurasidone groups combined, 34.4% for the olanzapine group, and 7.0% for the placebo group.

130 for the lurasidone groups compared with the olanzapine group.

131 d between the long-acting injection and oral olanzapine groups in general safety parameters.

132 ade 5 toxic effects, some patients receiving olanzapine had increased sedation (severe in 5%) on day

133 ia, and antipsychotics such as clozapine and olanzapine have been associated with differences in gene

134 s risk was increased equally with new use of olanzapine (hazard ratio (HR) = 1.64, 95% confidence int

135 New prescriptions of olanzapine (higher metabolic risk) declined during the w

136 Patients treated with olanzapine, however, had significantly greater weight ga

137 proate HR 0.24; 95% CI 0.09-0.61; p = 0.003, olanzapine HR 0.31; 95% CI 0.13-0.73; p = 0.007) and hyp

138 proate HR 0.25; 95% CI 0.10-0.60; p = 0.002, olanzapine HR 0.32; 95% CI 0.14-0.76; p = 0.008, quetiap

139 nfidence interval [CI] 0.45-0.69; p < 0.001, olanzapine HR 0.57; 95% CI 0.45-0.71; p < 0.001, quetiap

140 proate HR 1.62; 95% CI 1.31-2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47-2.30; p < 0.001, quetiap

141 e (HR 0.60; 95% CI 0.40-0.89; p = 0.012) and olanzapine (HR 0.48; 95% CI 0.29-0.77; p = 0.003), compa

142 % CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.44-0.77) compared with n

143 This study assessed the efficacy of olanzapine in delaying or preventing conversion to psych

144 Example images are shown for olanzapine in kidney and liver and imatinib in glioma.

145 tality rates associated with ziprasidone and olanzapine in real-world use.

146 ed risk of nonsuicidal mortality relative to olanzapine in real-world use; the study excludes a relat

147 as superior to risperidone, haloperidol, and olanzapine in terms of weight gain, and superior to risp

148 Adult rats were given either risperidone or olanzapine in their drinking water for 21 days.

149 y the superiority of clozapine compared with olanzapine in treatment-refractory childhood-onset schiz

150 f lurasidone, 120 mg of lurasidone, 15 mg of olanzapine (included to test for assay sensitivity), or

151 e used an experimental model that reproduces olanzapine-induced hyperphagia and obesity in female C57

152 Furthermore, olanzapine-induced hyperphagia and weight gain were blun

153 HTR2C-specific agonist lorcaserin suppressed olanzapine-induced hyperphagia and weight gain.

154 ting injection; a very low reference dose of olanzapine long-acting injection (45 mg every 4 weeks; N

155 to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatme

156 Olanzapine long-acting injection was efficacious in main

157 pine-treated patients (93%), as well as most olanzapine long-acting injection-treated patients receiv

158 high" (300 mg every 2 weeks; N=141) doses of olanzapine long-acting injection; a very low reference d

159 d 8% for the high, medium, low, and very low olanzapine long-acting treatment groups, respectively.

160 ctiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences bet

161 4R agonist xanomeline, or the antipsychotics olanzapine (M1R antagonist) and haloperidol (low M1R aff

162 Olanzapine may have an advantage for motor side effects.

163 agitation were randomly assigned to receive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean

164 Placental passage ratio was highest for olanzapine (mean=72.1%, SD=42.0%), followed by haloperid

165 discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), quetiapine (median, 5.3

166 3), or risperidone (median=2.8), but not for olanzapine (median=2.7).

167 nearly significant differences suggest that olanzapine might reduce the conversion rate and delay on

168 EXPOSURES Patients received olanzapine monotherapy for 8 weeks.

169 Patients taking clozapine and olanzapine must be examined for insulin resistance and i

170 ized to treatment with clozapine (n = 12) or olanzapine (n = 13).

171 ed lithium (n = 2148), valproate (n = 1670), olanzapine (n = 1477), or quetiapine (n = 1376) as maint

172 signed to treatment with clozapine (n = 37), olanzapine (n = 37), or haloperidol (n = 36).

173 onfidence interval [CI], 7.4 to 9.7 kg) with olanzapine (n = 45), by 6.1 kg (95% CI, 4.9 to 7.2 kg) w

174 nts were randomly assigned to treatment with olanzapine (N=133), quetiapine (N=134), or risperidone (

175 d to double-blind maintenance treatment with olanzapine (N=225) or placebo (N=136) for up to 48 weeks

176 patients randomly assigned to treatment with olanzapine (N=314) or risperidone (N=321), the authors a

177 or patients whose baseline antipsychotic was olanzapine (N=319), risperidone (N=271), or quetiapine (

178 ks; N=144); or their stabilized dose of oral olanzapine (N=322).

179 0.91 for ziprasidone (N=9,077) and 0.90 for olanzapine (N=9,077).

180 chotic not previously received in the trial (olanzapine [N=19], quetiapine [N=15], or risperidone [N=

181 done), extrapyramidal symptoms (NNH = 10 for olanzapine; NNH = 20 for risperidone), and urinary tract

182 apine (odds ratio: 1.52, 95% CI: 1.40-1.65), olanzapine (odds ratio: 1.56, 95% CI: 1.47-1.67), zipras

183 Atypical antipsychotics such as olanzapine often induce excessive weight gain and type 2

184 ed dosages; 32.1% received prescriptions for olanzapine (often at high dosages), 23.3% for more than

185 etine (4 weeks) or subchronic treatment with olanzapine (OLZ) (1 week) on ABA in BALB/cJ mice.

186 micromol/kg twice a day s.c. for 3 days) or olanzapine (OLZ) (4 to 15 micromol/kg twice a day for 3

187 Olanzapine (OLZ) is an atypical antipsychotic whose clin

188 ies of hydrophobic surface modifications for olanzapine (OLZ) loading by physical absorption to produ

189 difference between effects of clozapine and olanzapine on cortical thickness.

190 There was worsening with olanzapine on the BPRS withdrawn depression factor.

191 weeks) treatment with either haloperidol or olanzapine on the rat cortex.

192 s were significant compared with placebo for olanzapine only.

193 not affect the ability of the combination of olanzapine or aripiprazole and DVX to enhance ACh efflux

194 Pretreatment of olanzapine or aripiprazole with the selective serotonin

195 ect of the combination of DVX, 50 mg/kg, and olanzapine or aripiprazole, on DA efflux in both the HIP

196 promazine=13, haloperidol=316, intramuscular olanzapine or haloperidol injection=62, olanzapine=144,

197 n in phase 1 showed greater improvement with olanzapine or risperidone on the Neuropsychiatric Invent

198 monkeys chronically exposed to haloperidol, olanzapine, or placebo were also conducted.

199 rder who were prescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood stabilizer

200 [HR], 1.40; 95% CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS matching (H

201 ass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysi

202 m 18 macaque monkeys exposed to haloperidol, olanzapine, or sham long-term.

203 The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 th

204 nce showed a clinically important benefit of olanzapine over haloperidol in improving negative sympto

205 ienced sedation and delirium consistent with olanzapine overdose following possible accidental intrav

206 neurocognitive improvements of z = 0.13 for olanzapine (P<.002), 0.25 for perphenazine (P<.001), 0.1

207 on antipsychotics-aripiprazole, iloperidone, olanzapine, paliperidone, quetiapine, risperidone, rispe

208 During the treatment year, 16.1% of olanzapine patients and 37.9% of placebo patients experi

209 The olanzapine patients gained significantly more weight (me

210 Intervention Target doses of 15 to 20 mg of olanzapine per day plus masked sertraline or placebo at

211 zophrenia assigned to receive treatment with olanzapine, perphenazine, quetiapine fumarate, or risper

212 , patients were randomly assigned to receive olanzapine, perphenazine, quetiapine, risperidone, or zi

213 higher remission rates during the trial than olanzapine/placebo (odds ratio [OR], 1.28; 95% confidenc

214 All doses of olanzapine produced improved P20-N40 inhibitory processi

215 ine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) an

216 nts were randomly assigned to treatment with olanzapine, quetiapine fumarate, risperidone, or placebo

217 Olanzapine, quetiapine, and risperidone all produced sig

218 Olanzapine, quetiapine, and risperidone demonstrated com

219 sured by treatment discontinuation rates) of olanzapine, quetiapine, and risperidone in patients earl

220 The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in

221 The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitiv

222 nd-generation antipsychotics (eg, clozapine, olanzapine, quetiapine, and risperidone) are associated

223 As a group, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-r

224 f second-generation antipsychotic use (i.e., olanzapine, quetiapine, and risperidone) throughout the

225 scription for an antipsychotic (haloperidol, olanzapine, quetiapine, and risperidone), valproic acid

226 ation rates were 68.4%, 70.9%, and 71.4% for olanzapine, quetiapine, and risperidone, respectively.

227 justed absolute change in mortality risk for olanzapine, quetiapine, and risperidone.

228 e were 32 studies comprising 66 risperidone, olanzapine, quetiapine, and ziprasidone arms including 7

229 pical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asena

230 reatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid

231 Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks.

232 ial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole t

233 /dl who were on a stable treatment dosage of olanzapine, quetiapine, or risperidone were randomly ass

234 significantly longer for clozapine than for olanzapine, quetiapine, or risperidone.

235 Piracetam, amantadine, selegiline, olanzapine, quetiapine, risperidone, and citalopram do n

236 This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in

237 prazole, asenapine, iloperidone, lurasidone, olanzapine, quetiapine, risperidone, and ziprasidone.

238 omly to masked, flexible-dose treatment with olanzapine, quetiapine, risperidone, or placebo for up t

239 ly assigned to receive masked, flexible-dose olanzapine, quetiapine, risperidone, or placebo.

240 ine patients who discontinued treatment with olanzapine, quetiapine, risperidone, or ziprasidone in p

241 significantly greater for patients receiving olanzapine relative to patients receiving placebo (3.7 k

242 significantly greater for patients receiving olanzapine relative to patients receiving placebo, and a

243 gnificantly greater in patients treated with olanzapine relative to patients receiving placebo.

244 8-1.73) followed by risperidone (reference), olanzapine (relative risk=0.99, 95% CI=0.89-1.10), valpr

245 ases of diabetes may be attributed to use of olanzapine, risperidone, and quetiapine in patients taki

246 e, aripiprazole, chlorpromazine, quetiapine, olanzapine, risperidone, and ziprasidone all potently an

247 c drugs (APDs), e.g., clozapine, quetiapine, olanzapine, risperidone, and ziprasidone, have been repo

248 by more than 10% during less than 1 year of olanzapine, risperidone, or quetiapine therapy.

249 studied 15,767 patients who initiated use of olanzapine, risperidone, quetiapine, or haloperidol in 1

250 Treatment with olanzapine/sertraline was associated with higher remissi

251 t reduction in all outcome measures, whereas olanzapine showed a less consistent profile of clinical

252 ically among these patients, amisulpride and olanzapine showed superior efficacy versus haloperidol,

253 Olanzapine showed the greatest risk of weight gain and s

254 The results show that both risperidone and olanzapine significantly improved performance in object

255 crimination after 21 days, and additionally, olanzapine significantly increased cell proliferation in

256 ignificantly longer among patients receiving olanzapine than among patients receiving placebo.

257 nduced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after

258 Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight

259 ed controlled trial demonstrated that adding olanzapine to antiemetic prophylaxis reduces the likelih

260 endation Key updates include the addition of olanzapine to antiemetic regimens for adults who receive

261 ithium, as were rates of hypertension in the olanzapine treated group (HR 1.41, 95% CI 1.06-1.87; p =

262 ght gain > or =7% of baseline was higher for olanzapine-treated patients (41.9% versus 1.9%).

263 At 24 weeks, the majority of oral olanzapine-treated patients (93%), as well as most olanz

264 ant decreases in gray matter volume, whereas olanzapine-treated patients did not.

265 ceiving placebo, and a greater proportion of olanzapine-treated patients met response and remission c

266 cebo patients was about 2.5 times that among olanzapine-treated patients, which also approached signi

267 We found that olanzapine treatment acutely increased food intake, impa

268 ividuals, and response to an 8-week trial of olanzapine treatment in patients with schizophrenia.

269 or agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders

270 ood olanzapine treatment, although adulthood olanzapine treatment produced a significant increase in

271 expression that were unaffected by adulthood olanzapine treatment, although adulthood olanzapine trea

272 Starting 1 day after the end of olanzapine treatment, animals were behaviorally tested o

273 During olanzapine treatment, the most common emergent event was

274 uated improvement in negative symptoms after olanzapine treatment.

275 ased incidence of the metabolic syndrome for olanzapine versus haloperidol (risk differences, 2% and

276 g Scale (YMRS; range 0-60) up to 3 weeks for olanzapine versus placebo groups using eight increasingl

277 hors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-epi

278 nts with a baseline score of 20-25 (9.26 for olanzapine vs 6.70 for placebo; effect size 0.35, 95% CI

279 4R agonist xanomeline and the M1R antagonist olanzapine was able to inhibit (123)I-iododexetimide ex

280 Olanzapine was associated with at least one use of drugs

281 atment with both doses of lurasidone or with olanzapine was associated with significantly greater imp

282 ation observed after the 0.033 mg/kg dose of olanzapine was due to a selective decrease in response t

283 Olanzapine was effective in the treatment of bipolar man

284 Olanzapine was efficacious for positive prodromal sympto

285 zed mean difference; 95% credible interval), olanzapine was more effective than quetiapine (-0.29; -0

286 antipsychotic because of inefficacy (N=184), olanzapine was more effective than quetiapine and zipras

287 nt reductions in gray matter volume, whereas olanzapine was not.

288 In addition, olanzapine was significantly associated with decreases i

289 In multivariable analyses, olanzapine was significantly associated with higher trig

290 Olanzapine was superior to haloperidol and risperidone f

291 Olanzapine was superior to haloperidol in reducing the n

292 reatment with LY2140023, like treatment with olanzapine, was safe and well-tolerated; treated patient

293 The most common elicited adverse events for olanzapine were drowsiness (53%), weight gain (51%), and

294 h an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and zipra

295 en-label acute treatment with 5-20 mg/day of olanzapine were randomly assigned to double-blind mainte

296 received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabete

297 sses whether another atypical antipsychotic, olanzapine, will also improve sensory inhibition deficit

298 , randomised controlled trials that compared olanzapine with placebo, identified through searches of

299 ed, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethaso

300 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, a